We’ve recently updated our valuation analysis.

Soligenix Valuation

Is SNGX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SNGX?

Other financial metrics that can be useful for relative valuation.

SNGX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue17.5x
Enterprise Value/EBITDA-1x
PEG Ration/a

Price to Sales Ratio vs Peers

How does SNGX's PS Ratio compare to its peers?

The above table shows the PS ratio for SNGX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average19.3x
EFTR eFFECTOR Therapeutics
6.1x48.4%US$19.4m
ONVO Organovo Holdings
8.2xn/aUS$12.9m
ACOR Acorda Therapeutics
0.2xn/aUS$24.3m
LGVN Longeveron
62.7x89.3%US$82.2m
SNGX Soligenix
25.2x126.8%US$21.7m

Price-To-Sales vs Peers: SNGX is expensive based on its Price-To-Sales Ratio (25.2x) compared to the peer average (19.3x).


Price to Earnings Ratio vs Industry

How does SNGX's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a13.9%
n/an/an/a

Price-To-Sales vs Industry: SNGX is expensive based on its Price-To-Sales Ratio (25.2x) compared to the US Biotechs industry average (12.7x)


Price to Sales Ratio vs Fair Ratio

What is SNGX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SNGX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio25.2x
Fair PS Ratio23.8x

Price-To-Sales vs Fair Ratio: SNGX is expensive based on its Price-To-Sales Ratio (25.2x) compared to the estimated Fair Price-To-Sales Ratio (23.8x).


Share Price vs Fair Value

What is the Fair Price of SNGX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate SNGX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SNGX's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SNGX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$0.50
US$4.13
+725.0%
9.1%US$4.50US$3.75n/a2
Jan ’24US$0.45
US$4.13
+812.6%
9.1%US$4.50US$3.75n/a2
Dec ’23US$0.57
US$3.88
+573.9%
3.2%US$4.00US$3.75n/a2
Nov ’23US$0.68
US$3.88
+469.6%
3.2%US$4.00US$3.75n/a2
Oct ’23US$0.44
US$3.88
+787.3%
3.2%US$4.00US$3.75n/a2
Sep ’23US$0.77
US$3.88
+404.5%
3.2%US$4.00US$3.75n/a2
Aug ’23US$0.89
US$3.88
+336.6%
3.2%US$4.00US$3.75n/a2
Jul ’23US$0.58
US$3.88
+567.2%
3.2%US$4.00US$3.75n/a2
Jun ’23US$0.54
US$3.88
+618.4%
3.2%US$4.00US$3.75n/a2
May ’23US$0.53
US$4.88
+821.9%
23.1%US$6.00US$3.75n/a2
Apr ’23US$0.74
US$4.88
+558.8%
23.1%US$6.00US$3.75n/a2
Mar ’23US$0.68
US$4.88
+615.1%
23.1%US$6.00US$3.75n/a2
Feb ’23US$0.65
US$4.88
+651.9%
23.1%US$6.00US$3.75n/a2
Jan ’23US$0.66
US$4.88
+638.3%
23.1%US$6.00US$3.75US$0.452
Dec ’22US$0.82
US$4.88
+494.5%
23.1%US$6.00US$3.75US$0.572
Nov ’22US$1.00
US$4.88
+387.5%
23.1%US$6.00US$3.75US$0.682
Oct ’22US$1.05
US$4.88
+364.3%
23.1%US$6.00US$3.75US$0.442
Sep ’22US$1.06
US$4.88
+359.9%
23.1%US$6.00US$3.75US$0.772
Aug ’22US$0.95
US$3.75
+293.5%
60.0%US$6.00US$1.50US$0.892
Jul ’22US$1.10
US$3.75
+240.9%
60.0%US$6.00US$1.50US$0.582
Jun ’22US$1.05
US$4.42
+320.6%
46.8%US$6.00US$1.50US$0.543
May ’22US$1.44
US$4.75
+229.9%
41.4%US$6.50US$2.00US$0.533
Apr ’22US$1.56
US$4.31
+176.4%
43.3%US$6.50US$2.00US$0.744
Mar ’22US$1.63
US$4.31
+164.6%
43.3%US$6.50US$2.00US$0.684
Feb ’22US$1.58
US$4.31
+172.9%
43.3%US$6.50US$2.00US$0.654
Jan ’22US$1.28
US$4.44
+246.7%
45.5%US$7.00US$2.00US$0.664

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies